News coverage about Cerus (NASDAQ:CERS) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cerus earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.2701454671963 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Cerus (NASDAQ CERS) opened at $4.12 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.71 and a quick ratio of 3.11. Cerus has a 52-week low of $1.93 and a 52-week high of $4.70. The firm has a market cap of $474.93, a P/E ratio of -6.98 and a beta of 1.93.
Cerus (NASDAQ:CERS) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. The business had revenue of $10.80 million for the quarter, compared to the consensus estimate of $11.95 million. Cerus had a negative net margin of 159.35% and a negative return on equity of 142.18%. The company’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period last year, the firm earned ($0.14) earnings per share. sell-side analysts predict that Cerus will post -0.57 EPS for the current fiscal year.
CERS has been the topic of several research analyst reports. Cantor Fitzgerald set a $5.00 price target on shares of Cerus and gave the company a “buy” rating in a research report on Monday, January 8th. Cowen set a $6.00 price objective on shares of Cerus and gave the stock a “buy” rating in a report on Thursday, October 5th. Robert W. Baird restated a “buy” rating and issued a $5.00 price objective on shares of Cerus in a report on Friday, December 1st. Zacks Investment Research upgraded shares of Cerus from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a report on Wednesday, November 8th. Finally, BTIG Research reiterated a “neutral” rating on shares of Cerus in a report on Friday, December 8th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $5.83.
TRADEMARK VIOLATION NOTICE: This story was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://ledgergazette.com/2018/01/20/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-cerus-cers-stock-price.html.
Cerus Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.